ID
45184
Beschrijving
Principal Investigator: Michael A. Dyer, PhD, Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA MeSH: Retinoblastoma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000352 Retinoblastoma is a pediatric cancer of the developing retina. All retinoblastomas are believed to initiate with biallelic inactivation of the RB1 gene. To identify subsequent genetic lesions in retinoblastoma, we performed whole genome sequencing of tumor and normal DNA of 4 children with retinoblastoma and one matched orthotopic xenograft. Both alleles of RB1 were inactivated in the tumor samples. 3 of the patients had sporadic retinoblastoma and one patient had inherited retinoblastoma. Overall, there were few single nucleotide changes in coding regions of the genome and some of the tumors had few chromosomal lesions. There were very few new genetic lesions in the xenograft compared to the primary tumor. These data suggest that the genome in retinoblastoma is more stable than previously believed and there are relatively few recurrent genetic lesions in known cancer pathways other than the RB1 pathway.
Link
Trefwoorden
Versies (2)
- 20-08-22 20-08-22 - Simon Heim
- 12-10-22 12-10-22 - Adrian Schulz
Houder van rechten
Michael A. Dyer, PhD, Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA
Geüploaded op
12 oktober 2022
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
dbGaP phs000352 Sequencing of Retinoblastoma
This sample attributes table includes variables indicating the tumor/normal status, the body site where the sample was extracted, sample analyte type, histological type, primary tumor location, and whether sample was a xenograft. Note: the primary tumor location refers to the subject's primary tumor location and is independent from where the sample was extracted.
- StudyEvent: SEV1
- Eligibility Criteria
- This data table contains subject IDs and consent group information. The data table also includes a mapping of subject IDs to other subject ID aliases.
- The data table contains a mapping of subject ID to sample ID. Samples are the final preps submitted for sequencing. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes a mapping of sample IDs to other sample ID aliases.
- This subject phenotype table includes subjects diagnosed with retinoblastoma. The variables are was the disease sporadic or inherited, age at diagnosis, additional information regarding molecular testing, primary treatment protocol, relapse information, bone marrow transplant status, presence of genetic lesions, tumor purity, type of specimen and site where tissue was extracted. Additionally, there are 2 sociodemography variables: gender and ethnicity.
- This sample attributes table includes variables indicating the tumor/normal status, the body site where the sample was extracted, sample analyte type, histological type, primary tumor location, and whether sample was a xenograft. Note: the primary tumor location refers to the subject's primary tumor location and is independent from where the sample was extracted.
- This data table contains a mapping of sample ID to NCBI GEO accessions.
Similar models
This sample attributes table includes variables indicating the tumor/normal status, the body site where the sample was extracted, sample analyte type, histological type, primary tumor location, and whether sample was a xenograft. Note: the primary tumor location refers to the subject's primary tumor location and is independent from where the sample was extracted.
- StudyEvent: SEV1
- Eligibility Criteria
- This data table contains subject IDs and consent group information. The data table also includes a mapping of subject IDs to other subject ID aliases.
- The data table contains a mapping of subject ID to sample ID. Samples are the final preps submitted for sequencing. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes a mapping of sample IDs to other sample ID aliases.
- This subject phenotype table includes subjects diagnosed with retinoblastoma. The variables are was the disease sporadic or inherited, age at diagnosis, additional information regarding molecular testing, primary treatment protocol, relapse information, bone marrow transplant status, presence of genetic lesions, tumor purity, type of specimen and site where tissue was extracted. Additionally, there are 2 sociodemography variables: gender and ethnicity.
- This sample attributes table includes variables indicating the tumor/normal status, the body site where the sample was extracted, sample analyte type, histological type, primary tumor location, and whether sample was a xenograft. Note: the primary tumor location refers to the subject's primary tumor location and is independent from where the sample was extracted.
- This data table contains a mapping of sample ID to NCBI GEO accessions.
C1299222 (UMLS CUI [1,2])